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Abstract
Objective: Monoallelic de novo gain‐of‐function variants in the voltage‐gated so-
dium channel SCN8A are one of the recurrent causes of severe developmental and 
epileptic encephalopathy (DEE). In addition, a small number of de novo or inherited 
monoallelic loss‐of‐function variants have been found in patients with intellectual 
disability, autism spectrum disorder, or movement disorders. Inherited monoallelic 
variants causing either gain or loss‐of‐function are also associated with less severe 
conditions such as benign familial infantile seizures and isolated movement disor-
ders. In all three categories, the affected individuals are heterozygous for a SCN8A 
variant in combination with a wild‐type allele. In the present study, we describe two 
unusual families with severely affected individuals who inherited biallelic variants 
of SCN8A.
Methods: We identified two families with biallelic SCN8A variants by diagnostic 
gene panel sequencing. Functional analysis of the variants was performed using volt-
age clamp recordings from transfected ND7/23 cells.
Results: We identified three probands from two unrelated families with DEE due 
to biallelic SCN8A variants. Each parent of an affected individual carried a single 
heterozygous SCN8A variant and exhibited mild cognitive impairment without sei-
zures. In both families, functional analysis demonstrated segregation of one allele 
with complete loss‐of‐function, and one allele with altered biophysical properties 
consistent with partial loss‐of‐function.
Significance: These studies demonstrate that SCN8A DEE may, in rare cases, result 
from inheritance of two variants, both of which exhibit reduced channel activity. In 
these families, heterozygosity for the dominant variants results in less severe disease 
than biallelic inheritance of two variant alleles. The clinical consequences of variants 
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1 |  INTRODUCTION
SCN8A, encoding the voltage‐gated sodium channel Nav1.6, 
was first implicated in developmental and epileptic encepha-
lopathy (DEE) in 2012 in a heterozygous individual with a 
de novo variant.1 The phenotypic spectrum observed in sev-
eral hundred individuals now includes a range of epilepsies 
including benign familial infantile seizures with or without 
paroxysmal dyskinesia,2 less severe epilepsies with or with-
out comorbid intellectual disability (ID),3‒6 and severe early 
onset DEEs.1,7,8 Severe SCN8A DEE (Mendelian Inheritance 
in Man EIEE13) is characterized by intractable seizures with 
an average age at seizure onset of 4 months, cognitive deterio-
ration, pyramidal/extrapyramidal signs, progressive cerebral 
atrophy, and visual impairment leading to cortical blind-
ness.7‒9 There are often prolonged focal seizures with promi-
nent hypomotor and vegetative symptoms that may evolve to 
clonic or bilateral tonic‐clonic manifestations. Epileptic my-
oclonus, spasm‐like episodes, and recurrent convulsive status 
epilepticus are frequently observed.7‒9 All affected individu-
als described to date are monoallelic (heterozygous) carriers 
of a gain‐of‐function (GOF) or loss‐of‐function (LOF) vari-
ant in combination with a wild‐type (WT) allele.
Functional studies have demonstrated that SCN8A‐related 
epilepsies are typically caused by monoallelic GOF alter-
ations leading to neuronal hyperexcitability.1,10‒12 A small 
number of heterozygous LOF variants have been found in 
patients with ID, autism spectrum disorder (ASD), or move-
ment disorders who do not necessarily have epilepsy.10,13‒15 
The less severe familial SCN8A‐related disorders show an 
autosomal dominant pattern of inheritance, whereas the large 
majority of EIEE13 cases occur de novo.1‒5,7‒9,13‒15 A similar 
pattern has been reported for SCN2A, in which GOF variants 
cause early onset seizures, and LOF variants tend to be asso-
ciated with later onset seizures or with ID or ASD without 
epilepsy.16
In the mouse, homozygosity for partial LOF alleles 
of Scn8a results in movement disorders including ataxia, 
tremor, and dystonia, whereas complete LOF results in ju-
venile lethality with loss of ambulation.17,18 In the present 
paper, we describe the first two human families with biallelic 
variants in SCN8A. The index patients are born of heterozy-
gous parents who exhibit mild cognitive deficits, whereas the 
probands suffer from DEE and severe ID. Functional analysis 
demonstrated a shared mechanism of inheritance of one com-
plete LOF and one partial LOF allele by affected individuals 
in both families.
2 |  MATERIALS AND METHODS
2.1 | DNA sequencing
Both families underwent targeted gene panel sequencing as part 
of their formal diagnostic workup at either the Institute of Human 
Genetics, University of Leipzig Hospital and Clinics (Family 1) 
or the Danish Epilepsy Centre (Family 2). The parents or legal 
guardians of all probands provided written informed consent, 
and the study was approved by the local ethics committees. In 
Family 1, targeted sequencing of a custom panel of 131 genes 
associated with epilepsy (TruSight Rapid Capture Kit) was per-
formed. Genomic DNA was extracted from blood using stand-
ard methods, and the library was sequenced on a MiSeq v2 300 
sequencer (Illumina). In Family 2, targeted sequencing of 78 ep-
ilepsy genes was performed. Genomic DNA was extracted from 
blood using standard methods, and SureSelect library building 
was followed by sequencing on the Ion PGM system (Ion PGM 
200 Sequencing Kit), as previously described.19
Variants with a mutant allele frequency < 1% in the 
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with partial and complete loss of SCN8A function are variable and likely to be influ-
enced by genetic background.
Key Points
• Biallelic inherited loss‐of‐function SCN8A variants 
were identified in probands with developmental 
and epileptic encephalopathy
• Their heterozygous parents exhibited mild cogni-
tive impairment without epilepsy
• Functional analysis demonstrated segregation of 
one allele with complete loss‐of‐function and one 
with partial loss‐of‐function in both families
• These dominant variants result in partial or com-
plete loss‐of‐function of the voltage‐gated sodium 
channel Nav1.6 and result in mild cognitive impair-
ment in heterozygous carriers and severe DEE in 
individuals inheriting two mutant alleles
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classified according to the ACMG guidelines.20 In sil-
ico evaluation was performed using SIFT Blink (J. 
Craig Venter Institute), Polyphen2 (Harvard), Combined 
Annotation‐Dependent Depletion (CADD; University of 
Washington), MutationTaster (Charité), Model Predictive 
Control (MPC; Harvard), and the following splicing tools: 
SpliceSiteFinder‐like, MaxEntScan, NNSPLICE, and 
Human Splicing Finder. In addition, database synchro-
nization by ClinVar (National Center for Biotechnology 
Information) and Human Gene Mutation Database 
(Biobase) was performed. Sanger sequencing was carried 
out to confirm all variants and to perform segregation 
analysis.
2.2 | Electrophysiology
Missense variants were introduced into the tetrodotoxin‐re-
sistant mouse cDNA Nav1.6R by site‐directed mutagenesis 
with QuikChange II XL (Agilent Technologies) and analyzed 
as previously described.12 The 6‐kb open reading frame of 
each construct was resequenced to eliminate clones contain-
ing extraneous mutations. Nav1.6 variants were expressed 
by transfection of neuron‐derived ND7/23 cells (Sigma‐
Aldrich).12 Sodium currents were recorded 48  hours after 
transfection in the presence of 500 nmol·L–1 tetrodotoxin to 
block endogenous sodium currents, using the whole‐cell con-
figuration of the patch‐clamp recording technique.12





Patient B Family 2
Sex M F M
Current age 4 y 2 y 27 y
Family history Both parents: mild cognitive deficits. 
Two maternal uncles and one maternal 
aunt have ID ± epilepsy. One maternal 
half‐brother has speech delay.
Both parents: mild cognitive deficits. 
Two maternal uncles and one maternal 
aunt have ID ± epilepsy. One maternal 
half‐brother has speech delay.
Both parents have mild cogni-
tive deficits.
Development Severe ID Severe ID Profound ID
Age at seizure onset 3 mo Few hours after birth 7 mo
Seizure type at onset Focal seizure Convulsive status epilepticus Tonic seizure and eye rolling
Seizure types Clonic, focal, or brief tonic seizures Brief tonic and automotor seizures Infantile febrile seizures, 
tonic seizures, absences
EEG features 12 m: hypsarrhythmia; 3 y: moderate 
background slowing; mild nonspecific 
EEG abnormalities
8 d: medium‐weight generalized dis-
charges; 4 m: hypsarrhythmia; 17 mo: 
moderate background slowing; mild 
nonspecific EEG abnormalities
7 y: ictal regular generalized 
3‐4–Hz paroxysms of 5‐10 s; 
26 y: 3‐4–Hz spike‐waves 
bilaterally in the posterior 
quadrants
Movement disorder No No Dyskinesia
Other neurological 
features
Hypotonia, strabismus; 19 mo: auditory 
neuropathy
Hypotonia, 8 mo: strabismus Hypotonia, spastic tetraplegia
Vision impairment 6 mo: VEP/flash‐VEP; binocular re-
sponse pos; hyperopia
11 mo: hyperopia Myopia
Additional features Bilateral hip dysplasia, constipation, 
hemangioma, swallowing difficulties, 
regurgitation; 28 m: microcephaly 
(−3.4 SD)
Constipation, swallowing difficulties, 
apnea, dysphagia; 5 mo: microcephaly 
(−5 SD); 13 mo: PEG tube
Recurrent pneumonia, con-
stipation; phimosis, reflux, 
asthma, bilateral hip dys-
plasia, dysphagia, scoliosis, 
kyphosis
MRI 4 mo and 26 mo: pineal cyst, otherwise 
normal
4 mo: delayed myelination 8 y: cerebral atrophy
Allele 1 c.805G>A; p.(Gly269Arg) mat c.805G>A; p.(Gly269Arg) mat c.2464G>A; p.(Gly822Arg) 
pat
Allele 2 c.4079C>A; p.(Thr1360Asn) pat c.4079C>A; p.(Thr1360Asn) pat c.4912C>T; p.(Arg1638Cys) 
mat
Abbreviations: EEG, electroencephalogram; F, female; ID, intellectual disability; M, male; mat, maternal; MRI, magnetic resonance imaging; pat, paternal; PEG, 
percutaneous endoscopic gastrostomy; pos, positive; VEP, visually evoked potential.
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3 |  RESULTS
3.1 | Clinical features of affected children 
and parents from two families segregating 
biallelic SCN8A variants
The clinical data of the three index patients are summarized 
in Table 1.
3.1.1 | Family 1
The index patients were a sib pair (3‐year‐old male and 2‐
year‐old female) born to unrelated parents (Figure 1A). Both 
parents had mild cognitive impairment/borderline intel-
lectual functioning. They both attended special school, ob-
tained vocational training, and were able to live independent 
lives. Neuropsychological evaluations were not available. 
Additional affected family members included a maternal 
half‐brother of the affected sibs and two of the mother's half‐
brothers and one half‐sister, all with mild ID and one with 
unclassified epilepsy. Unfortunately, none of the maternal 
relatives were available for genetic testing.
The male sib was born at term after an uncomplicated preg-
nancy and delivery (Apgar 10/10). Postnatally, he needed treat-
ment of hypoglycemia and was tube fed for several days due to 
feeding difficulties. He presented with global developmental 
delay and onset of intractable daily focal seizures at 3 months 
of age. Treatment with levetiracetam (LEV) was initiated, 
which led to transient seizure reduction. However, during the 
course of the disease, he developed clonic and daily brief tonic 
seizures (lasting a few seconds). His initial electroencepha-
logram (EEG) showed background slowing and multifocal 
epileptiform discharges, which progressed to hypsarhythmia. 
Treatment with sulthiame and prednisolone was tried without 
any effect. Magnetic resonance imaging (MRI) performed at 
4 months of age was normal, except for a small pineal cyst. At 
follow‐up, he presented with muscular hypotonia, severe ID, 
and microcephaly (−3.4 SD at 28 months). Additional features 
included strabismus, hyperopia, and bilateral hip dysplasia 
(type IIa on the right and type Ib on the left side). At 19 months 
of age, bilateral coxa valga was observed and confirmed by X‐
ray. Furthermore, he suffered from constipation and swallow-
ing difficulties with regurgitation and vomiting after chunky 
food. At 19 months of age, he was diagnosed with an auditory 
neuropathy with almost complete hearing loss. He could turn 
to both sides at 30 months of age, but was not able to sit, crawl, 
stand, walk, or communicate. His epilepsy continued to be in-
tractable, and currently he has one to two brief tonic seizures 
per week despite treatment with LEV, vigabatrin (VGB), and 
valproic acid (VPA). EEG at follow‐up showed background 
slowing and mild nonspecific abnormalities.
The female sib was born at term after a risk pregnancy due 
to maternal hypertension. Birth and postnatal adaptation were 
complicated by perinatal asphyxia and left cerebral hemor-
rhage (Apgar 1/1/2). Postnatally, she presented with hypoxic 
ischemic encephalopathy, and when only a few hours old she 
developed convulsive status epilepticus. She presented with 
daily dyscognitive seizures and brief focal motor seizures with 
a tonic component. She continued to have episodes of convul-
sive status epilepticus. EEG showed multifocal epileptiform 
discharges, which evolved to hypsarrhythmia at 4 months of 
age. At 10 months of age, she suffered from daily brief tonic 
seizures. She was developmentally delayed from birth, and 
severe ID was present at follow‐up. MRI at 4 months of age 
showed delayed myelination. At 5 months of age, severe micro-
cephaly was evident (−5 SD). At follow‐up, she had adequate 
head control and was able to grab things, but was unable to turn 
or sit, and had poor eye contact. Additional features included 
hyperopia, strabismus, constipation, hypotonia, apneas, and 
eating difficulties. Tube feeding was initiated at 13 months.
She experienced a transient response to phenobarbital, 
and her EEG improved during treatment with prednisolone, 
5 mg/kg/d for 2 weeks, showing only background slowing and 
nonspecific EEG abnormalities. VGB and sulthiame treat-
ment resulted in no seizure improvement. Current treatment 
F I G U R E  1  Biallelic inheritance of developmental and epileptic 
encephalopathy (DEE) in two families, and the protein location of the 
novel variants. A, Individuals affected with DEE (epilepsy plus severe 
intellectual disability [ID]) are compound heterozygotes for inherited 
variants of SCN8A. Heterozygous parents exhibit mild cognitive 
deficits. Sanger sequencing of genomic DNA demonstrated inheritance 
of two mutant alleles by individuals affected with DEE (epilepsy with 
severe ID) and a single variant in heterozygous carriers with mild 
cognitive deficits. B, Location of four novel variants in the voltage‐
gated sodium channel SCN8A. BIF, borderline intellectual functioning.
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includes sulthiame and VPA and is accompanied by 10‐15 
absence seizures per day.
3.1.2 | Family 2
The proband was a 27‐year‐old male born to unrelated parents. 
Both parents had mild cognitive deficits. They were able to live 
independent lives with guidance and support. Both attended 
special school, received disability pensions, and worked in a 
sheltered workshop. Neuropsychological evaluations were not 
available, and both parents were lost for follow‐up.
The patient was born at term after an uncomplicated preg-
nancy and delivery. He was readmitted to the hospital within the 
first week of life due to cyanosis, hypotonia, and apathetic be-
havior. At 6 months of age, delayed psychomotor development 
became evident (no eye contact, lack of head control, hypotonia), 
and at 7 months of age, he experienced his first seizure, charac-
terized by eye rolling and stiffness of the whole body. His EEG 
was reported as slightly abnormal, but no antiepileptic treatment 
was initiated. A computed tomography scan showed atrophy of 
the frontal lobes. At this approximate age, he was removed from 
his parents and put in foster care. In the following years, he was 
diagnosed with severe ID, spastic tetraplegia, myopia, and bilat-
eral hip dysplasia. He never gained the ability to walk or com-
municate, and was admitted several times due to febrile seizures, 
asthmatic bronchitis, gastroesophageal reflux, pneumonia, and 
constipation. At the age of 7 years, brief episodes with staring 
were noticed. Ictal EEG recordings showed regular diffuse 3‐4–
Hz epileptic discharges lasting for 5‐10 seconds. Oxcarbazepine 
was introduced but was administered irregularly for a few days 
by the foster mother, only during febrile episodes. At 8.5 years, 
it was stopped. MRI performed at the age of 8 years did not 
show abnormalities. When he was 9 years old, he was moved to 
a residential care institution, where he now lives. Tonic‐clonic 
seizures, occasional dystonic/dyskinetic episodes, and eating 
difficulties were reported. At the age of 10  years, topiramate 
(TPM) and VPA were initiated, achieving seizure control for 
some years. He was also treated with risperidone for behavioral 
problems (agitation and screaming). At age 15 years, TPM was 
stopped. In the following years, the seizure frequency progres-
sively increased, and at 20 years of age, he was referred to the 
Danish Epilepsy Center because of drug‐resistant epilepsy with 
weekly tonic seizures and staring episodes. His interictal EEG 
showed subcontinuous theta‐delta activity and high‐amplitude 
spike and slow waves, bilaterally in the posterior quadrants, as 
well as less prominent focal slowing and infrequent spike and 
slow waves in the frontotemporal regions. The staring episodes 
were recorded on video‐EEG and did not have an EEG correlate. 
LEV was added to VPA, with improvement of seizure duration 
and frequency from weekly to monthly. At latest examination, 
he was profoundly intellectually disabled, nonverbal, and wheel-
chair bound and had spastic tetraplegia, dyskinesia, dysphagia, 
scoliosis, kyphosis, and severe myopia.
3.2 | Identification and inheritance of 
SCN8A mutations
3.2.1 | Family 1
Gene panel testing revealed that the two affected sibs were 
compound heterozygotes for the SCN8A missense variants 
p.Gly269Arg (c.805G>A) located in the pore loop of do-
main I and p.Thr1360Asn (c.4079C>A) in the pore loop of 
domain 3 (Figure 1B). Sanger sequencing demonstrated that 
both variants were inherited (Figure 1B).
3.2.2 | Family 2
Gene panel sequencing revealed that the index patient was 
compound heterozygous for the SCN8A missense variants 
p.Gly822Arg (c.2464G>A) located in the middle of trans-
membrane segment D2S3 and p.Arg1638Cys (c.4912C>T) 
at the cytoplasmic end of transmembrane segment D4S4. 
Sanger sequencing demonstrated that both variants were in-
herited (Figure 1B).
SCN8A is highly intolerant of variation in the general 
population, with a probability of LOF intolerance of 1.00 
and a missense z score of 7.94 in the gnomAD database. 
There are only four protein truncations and 384 missense 
variants in the gnomAD database,21 compared to the pre-
diction of 80 truncations and 1114 missense variants. The 
four variants detected in the present study are absent from 
the gnomAD database and are predicted to be deleteri-
ous by two or more prediction programs including CADD 
score, MPC score, and PolyPhen.
3.3 | Functional analysis of SCN8A variants
ND7/23 cells were transfected with Nav1.6 cDNA, and so-
dium currents were recorded. Cells transfected with WT 
Nav1.6 generated current density of −90 ± 11 pA/pF (n = 37; 
Figure 2A). Transfection of variant G269R from Family 1 
(allele 1) did not generate any detectable current (−6 ± 1.4 
pA/pF, n = 5; Figure 2B) and was not significantly differ-
ent (P  >  .05) from nontransfected cells (−4  ±  0.8 pA/pF, 
n = 5). In contrast, the variant T1360N (Family 1, allele 2) 
generated current density similar in magnitude to the WT 
channel (−82 ± 17 pA/pF, n = 7; Figure 2C). The voltage 
dependence of activation of T1360N channels did not dif-
fer from WT (Figure 2D,E; Table 2). However, analysis of 
voltage‐dependent steady‐state inactivation demonstrated a 
hyperpolarizing shift of −7.5 mV in the half maximal voltage 
of inactivation (V1/2) of T1360N compared to WT (P < .01; 
Figure 3F‐H, Table 2). The predicted effect of this mutation 
is to reduce channel availability.
Family 2 allele 1 (G822R) did not generate detectable 
sodium current (−7  ±  1 pA/pF, n  =  12; Figure 3B,3D). 
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Family 2 allele 2 (R1638C) generated current density of 
−63 ± 8.7 pA/pF (n = 12), which did not differ from WT 
(P > .05; Figure 3C,3D). The V1/2 for activation of R1638C 
was shifted in a depolarizing direction by  +3.8  mV in 
comparison with the WT channels (P < .05; Figure 3F‐H, 
Table 2). This is predicted to reduce the number of channel 
openings at a given voltage. The V1/2 for steady‐state inac-
tivation between R1638C and WT channels did not differ 
(Figure 3E, Table 2). The depolarizing shift in voltage‐de-
pendent activation exhibited by R1638C is consistent with 
reduced neuronal activity.
4 |  DISCUSSION
We describe two pedigrees (Figure 1) in which probands 
with inherited biallelic variants of SCN8A are severely af-
fected with DEE. The monoallelic (heterozygous) parents 
have only mild cognitive deficits. In each family, one par-
ent had a more severe allele with complete LOF and one 
parent had a partial LOF variant, with the probands inher-
iting one of each type of variant. These variants exhibit 
dominant expression in heterozygous carriers with mild 
phenotypes and a much more severe phenotype in com-
pound heterozygous carriers with two variant alleles. None 
of the four variants had been previously described in pa-
tients, but all are predicted to likely be pathogenic and are 
absent from the control population in the gnomAD data-
base.22 Functional tests demonstrated reduced or complete 
LOF of the variant channels. In the only previous report of 
a patient with two variants of SCN8A, the missense vari-
ant (p.Ile1583Thr) was probably not deleterious, and the 
deletion was a somatic mosaic.23 In two families with bi-
allelic variants of CACNA1A, the probands with biallelic 
variants suffered from DEE whereas the heterozygous par-
ents and siblings had milder symptoms,24,25 similar to our 
observations.
In addition to demonstrating a previously unreported 
inheritance pattern for SCN8A‐related disorders, these 
families suggest an explanation for the observation that 
the frequency of SCN8A variants previously observed 
is lower than that for SCN1A (Johannesen et al, personal 
communication).26 In contrast to SCN1A heterozygotes, 
who are often affected with Dravet syndrome, the SCN8A 
F I G U R E  2  Biophysical characterization of sodium channel variants in Family 1. A‐C, Representative traces of families of sodium channel 
currents recorded from ND7/23 cells expressing wild type (WT; A), G269R (B), and T1360N (C). D, Averaged current‐voltage curves for WT 
(n = 37) and T1360N (n = 7). E, Voltage dependence of channel activation. F, G, Example traces of steady‐state inactivation curves for WT (F) 
and T1360N (G). Inset shows voltage protocol for steady‐state inactivation (Vcmd: voltage command). H, Voltage dependence of steady‐state 
inactivation for WT (n = 37) and T1360N (n = 7). Data represent mean ± SEM. Smooth lines in D and H correspond to single Boltzmann equation 
fits to average data
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heterozygotes presented in this study were not sufficiently 
ill to be candidates for genetic testing. There are likely to 
be many more individuals with mild SCN8A‐related pheno-
types who will not be discovered until genetic testing be-
comes more widespread.
Electrophysiological analysis of the variants G269R and 
G822R identified complete absence of channel activity in 
transfected ND7/23 cells. G269R is located in segment 5 of 
domain I, and G822R is located in segment 3 of domain 2, a 
region that is relatively lacking in variants causing dominant 
DEE.11 Both variants completely eliminate channel activity, 
indicating that the affected residues are essential for chan-
nel function. In contrast, the variants R1638C and T1360N 
retained channel activity with altered biophysical properties 
that are consistent with partial LOF. Depolarizing shifts of 
voltage‐dependent activation in the R1638C mutation reduce 
the number of channels available to open at any membrane 
voltage and thereby reduce neuronal excitability. The hyper-
polarized shift in channel inactivation in the T1360N channel 
reduces channel availability due to premature entry into inac-
tivated channel states. The predicted result in affected com-
pound heterozygotes is altered excitability of both excitatory 
T A B L E  2  Activation and inactivation parameters of wild‐type and variant Nav1.6 currents
 
Activation Inactivation
V1/2, mV k V1/2, mV k
WT, n = 37 −25.8 ± 0.8 5.37 ± 0.22 −66.9 ± 0.9 7.75 ± 0.14
Family 1, allele 2 T1360N, n = 7 −26.0 ± 1.6 5.29 ± 0.47 −74.4 ± 1.6* 7.79 ± 0.35
Family 2, allele 2 R1638C, n = 12 −22.0 ± 0.8** 6.65 ± 0.29* −66.7 ± 2.0 10.4 ± 0.88*** 
Abbreviations: WT, wild type; V1/2, half maximal voltage of inactivation.
*P < .01, **P < .05, ***P < .001 compared to WT by unpaired t test. 
F I G U R E  3  Biophysical characterization of sodium channel variants in Family 2. A‐C, Representative traces of families of sodium channel 
currents recorded from ND7/23 cells expressing wild type (WT; A), G822R (B), and R1648C (C). D, Averaged current‐voltage curves for WT 
(n = 37), G822R (n = 9), and R1638C (n = 12). E, Voltage dependence of steady‐state inactivation for WT (n = 37) and R1638C (n = 12). F, G, 
Example traces of sodium currents recorded for WT (F) and R1638C (G) showing a reduction in current amplitude in R1648C cells compared 
with WT at a given activation voltage. Inset shows activation voltage protocol. H, Voltage dependence of activation for WT (n = 37) and R1638C 
(n = 12). Data represent mean ± SEM. Smooth lines in E and H correspond to single Boltzmann equation fits to average data
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and inhibitory neurons, modulating overall neuronal network 
function.
Both families segregate one allele with complete LOF 
and one allele with altered biophysical properties, both of 
which are predicted to result in reduced neuronal activity. In 
contrast, most of the de novo variants associated with DEE 
result in elevated neuronal activity.11 The most common 
biophysical effect of previously described SCN8A variants 
in DEE is impaired channel inactivation and elevated neuro-
nal activity, for example, the recurrent variant R1872W.12,27 
Even in the presence of a WT allele, variants with elevated 
channel activity produce a severe dominant phenotype. 
However, for the LOF variants, the WT allele in heterozy-
gous carriers provides compensating channel activity and 
heterozygous parents exhibit only mild cognitive deficits. 
In the individuals affected with DEE, who are compound 
heterozygotes for reduced function alleles, the total channel 
activity is predicted to be <50% of normal, resulting in the 
severe phenotype of SCN8A encephalopathy. However, it is 
not clear why reduced activity of Nav1.6 results in seizures. 
The biallelic LOF individuals in our families have pheno-
types that are indistinguishable from monoallelic GOF vari-
ants, including early onset DEE with multiple seizure types 
(focal, clonic, and tonic), severe ID with absent speech, 
axial hypotonia, central visual impairment, microcephaly, 
and gastrointestinal symptoms, features that are all de-
scribed in patients with elevated channel activity.7 It cannot 
be excluded that other rare genetic variants may contribute 
to the observed phenotypes.
A small number of heterozygous carriers of partial or 
complete LOF of SCN8A have been described previously, 
with variable consequences. Myoclonus in the absence of 
seizures was observed in one family with four affected fam-
ily members.15 Mild to moderate ID or ASD in the absence 
of seizures was observed in four families.10,14 On the other 
hand, absence epilepsy was observed in a family with the 
heterozygous protein truncating variant p.Asn544fs*39,6 
and focal epilepsy with mild ID was observed for the protein 
truncation variant p.Arg1820*0.28 It is likely that variations 
in other genes in the genetic background contribute to this 
variation; the effects of modifier genes on seizure phenotypes 
have been well established in the mouse.18,29 It is also possi-
ble that missense variants that appear to cause complete LOF 
in vitro may actually retain some activity in vivo that con-
tributes to the relatively mild phenotype in the monoallelic 
(heterozygous) parents. Recent evidence suggests that the 
sodium channel alpha subunits may function as dimers.30 In 
this case, LOF alleles that produce full length protein could 
have a dominant negative effect in heterozygotes, resulting 
in <50% residual activity and a more severe phenotype than 
that of LOF alleles encoding truncated or unstable proteins.
SCN8A is widely expressed in both excitatory and inhib-
itory neurons of the central nervous system and peripheral 
nervous system. LOF variants of Scn8a in the mouse re-
sult in severe movement disorders without seizures; loss of 
90% of normal activity results in tremor, ataxia, and dys-
tonias,18 and loss of 100% of activity results in hind limb 
paralysis and juvenile lethality.17 Homozygosity for com-
plete LOF alleles may also be incompatible with human 
life. Reduced activity of Nav1.6 in colonic mesenteric neu-
rons may contribute to the gastrointestinal disturbances in 
patients with SCN8A encephalopathy.31 Future studies of 
inhibitory neuron populations in SCN8A encephalopathy 
could be helpful to reconcile the existence of both GOF 
and LOF variants in patients with developmental and epi-
leptic encephalopathy.
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